Expression of Mfn2, the Charcot-Marie-Tooth neuropathy type 2A gene, in human skeletal muscle: effects of type 2 diabetes, obesity, weight loss, and the regulatory role of tumor necrosis factor alpha and interleukin-6.
The primary gene mutated in Charcot-Marie-Tooth type 2A is mitofusin-2 (Mfn2). Mfn2 encodes a mitochondrial protein that participates in the maintenance of the mitochondrial network and that regulates mitochondrial metabolism and intracellular signaling. The potential for regulation of human Mfn2 gene expression in vivo is largely unknown. Based on the presence of mitochondrial dysfunction in insulin-resistant conditions, we have examined whether Mfn2 expression is dysregulated in skeletal muscle from obese or nonobese type 2 diabetic subjects, whether muscle Mfn2 expression is regulated by body weight loss, and the potential regulatory role of tumor necrosis factor (TNF)alpha or interleukin-6. We show that mRNA concentration of Mfn2 is decreased in skeletal muscle from both male and female obese subjects. Muscle Mfn2 expression was also reduced in lean or in obese type 2 diabetic patients. There was a strong negative correlation between the Mfn2 expression and the BMI in nondiabetic and type 2 diabetic subjects. A positive correlation between the Mfn2 expression and the insulin sensitivity was also detected in nondiabetic and type 2 diabetic subjects. To determine the effect of weight loss on Mfn2 mRNA expression, six morbidly obese subjects were subjected to weight loss by bilio-pancreatic diversion. Mean expression of muscle Mfn2 mRNA increased threefold after reduction in body weight, and a positive correlation between muscle Mfn2 expression and insulin sensitivity was again detected. In vitro experiments revealed an inhibitory effect of TNFalpha or interleukin-6 on Mfn2 expression in cultured cells. We conclude that body weight loss upregulates the expression of Mfn2 mRNA in skeletal muscle of obese humans, type 2 diabetes downregulates the expression of Mfn2 mRNA in skeletal muscle, Mfn2 expression in skeletal muscle is directly proportional to insulin sensitivity and is inversely proportional to the BMI, TNFalpha and interleukin-6 downregulate Mfn2 expression and may participate in the dysregulation of Mfn2 expression in obesity or type 2 diabetes, and the in vivo modulation of Mfn2 mRNA levels is an additional level of regulation for the control of muscle metabolism and could provide a molecular mechanism for alterations in mitochondrial function in obesity or type 2 diabetes.
Bach
Daniel
D
Universitat de Barcelona, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Avda. Diagonal 645, Barcelona, Spain.
Naon
Deborah
D
Pich
Sara
S
Soriano
Francesc X
FX
Vega
Nathalie
N
Rieusset
Jennifer
J
Laville
Martine
M
Guillet
Christelle
C
Boirie
Yves
Y
Wallberg-Henriksson
Harriet
H
Manco
Melania
M
Calvani
Menotti
M
Castagneto
Marco
M
Palacín
Manuel
M
Mingrone
Geltrude
G
Zierath
Juleen R
JR
Vidal
Hubert
H
Zorzano
Antonio
A
D002607:Charcot-Marie-Tooth Disease / Q000235:genetics; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000503:physiopathology*; D005260:Female; D020558:GTP Phosphohydrolases; D015870:Gene Expression; D005786:Gene Expression Regulation / Q000502:physiology; D006801:Humans; D007328:Insulin / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology*; D008297:Male; D008565:Membrane Proteins / Q000096:biosynthesis*; D008875:Middle Aged; D024101:Mitochondrial Proteins / Q000096:biosynthesis*; D018482:Muscle, Skeletal / Q000378:metabolism; D009765:Obesity / Q000235:genetics / Q000503:physiopathology*; D012333:RNA, Messenger / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000502:physiology*; D015431:Weight Loss / Q000235:genetics / Q000502:physiology*
D007328:Insulin; D015850:Interleukin-6; D008565:Membrane Proteins; D024101:Mitochondrial Proteins; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D020558:GTP Phosphohydrolases; C470018:MFN2 protein, human